Literature DB >> 1800765

The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma.

F Lloyd1, M Goldrosen.   

Abstract

A standard hybridoma fusion technique was used to produce a monoclonal antibody capable of binding both carcinoembryonic antigen (CEA) and the hapten 4-amino-phthalate. A hypoxanthine-aminopterin-thymidine (HAT) sensitive anti-CEA hybridoma and KLH-phthalate immunized spleen cells were hybridized to yield clones producing bispecific monoclonal antibodies. The desired bispecific antibody was identified using both enzyme-linked immunosorbent assay (ELISA) and radio-immunoassay. The resultant hybrid-hybridoma or "tridoma" was subcloned and expanded to yield a stable population. Bifunctional antibody was then isolated from the various possible recombinants by ion exchange chromatography. This general method may be used to produce bispecific monoclonals against a wide variety of tumor associative antigens and reagents for immunodetection or treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800765      PMCID: PMC2571588     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  12 in total

Review 1.  Serotherapy of cancer.

Authors:  D T Harris; M J Mastrangelo
Journal:  Semin Oncol       Date:  1989-06       Impact factor: 4.929

2.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

Authors:  A Lanzavecchia; D Scheidegger
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

3.  Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients.

Authors:  G Laurent; J Pris; J P Farcet; P Carayon; H Blythman; P Casellas; P Poncelet; F K Jansen
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

4.  Hybrid hybridomas and their use in immunohistochemistry.

Authors:  C Milstein; A C Cuello
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

5.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.

Authors:  U D Staerz; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.

Authors:  H F Sears; B Atkinson; J Mattis; C Ernst; D Herlyn; Z Steplewski; P Häyry; H Koprowski
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

7.  Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.

Authors:  R O Dillman; D L Shawler; J B Dillman; I Royston
Journal:  J Clin Oncol       Date:  1984-08       Impact factor: 44.544

8.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments.

Authors:  J A Carrasquillo; K A Krohn; P Beaumier; R W McGuffin; J P Brown; K E Hellström; I Hellström; S M Larson
Journal:  Cancer Treat Rep       Date:  1984-01

9.  A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells.

Authors:  M L Gefter; D H Margulies; M D Scharff
Journal:  Somatic Cell Genet       Date:  1977-03

10.  Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.

Authors:  J R Corvalan; W Smith
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.